Adicet Bio, Inc. Payments to Acquire Marketable Securities
Adicet Bio, Inc. (ACET) reported Payments to Acquire Marketable Securities of $5.70 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2022-03-15
- Adicet Bio, Inc. payments to acquire marketable securities for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. payments to acquire marketable securities for the quarter ending 2020-09-30 was $0.00.
- Adicet Bio, Inc. payments to acquire marketable securities for the quarter ending 2020-06-30 was $0.00.
- Adicet Bio, Inc. payments to acquire marketable securities for the quarter ending 2020-03-31 was $5.70M, a 92.61% decline year-over-year.
- Adicet Bio, Inc. payments to acquire marketable securities for fiscal 2020 was $5.70M, a 92.51% decline from fiscal 2019.
- Adicet Bio, Inc. payments to acquire marketable securities for fiscal 2019 was $76.08M, a 401.11% increase from fiscal 2018.
- Adicet Bio, Inc. payments to acquire marketable securities for fiscal 2018 was $15.18M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | $5.70M 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $5.70M 10-Q · filed 2021-11-10 | $21.72M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $5.70M 10-Q · filed 2021-08-12 | $21.72M derived: sum of 3 quarters · filed 2021-08-12 | $4.67M derived: sum of 4 quarters · filed 2021-08-12 | ||
| 2020-03-31 | $5.70M 10-Q · filed 2021-05-17 | $21.72M derived: sum of 2 quarters · filed 2021-05-17 | $4.67M derived: sum of 3 quarters · filed 2021-05-17 | $4.67M derived: sum of 4 quarters · filed 2021-05-17 | ||
| 2019-12-31 | $16.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$1.03M derived: sum of 2 quarters · filed 2021-03-12 | -$1.03M derived: sum of 3 quarters · filed 2021-03-12 | $76.08M 10-K · filed 2021-03-12 | $97.10M 10-K · filed 2020-03-12 | |
| 2019-09-30 | -$17.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$17.05M derived: sum of 2 quarters · filed 2020-11-05 | $60.06M 10-Q · filed 2020-11-05 | $97.10M 10-Q · filed 2019-11-05 | -$17.05M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $77.10M 10-Q · filed 2020-07-30 | -$7.00K derived: sum of 3 quarters · filed 2021-03-12 | $17.74M derived: sum of 4 quarters · filed 2021-03-12 | ||
| 2019-03-31 | $77.10M 10-Q · filed 2020-05-07 | -$7.00K derived: sum of 2 quarters · filed 2021-03-12 | $17.74M derived: sum of 3 quarters · filed 2021-03-12 | |||
| 2018-12-31 | -$77.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$59.36M derived: sum of 2 quarters · filed 2021-03-12 | $15.18M 10-K · filed 2021-03-12 | $107.85M 10-K · filed 2019-03-18 | ||
| 2018-09-30 | $17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $92.29M 10-Q · filed 2019-11-05 | ||||
| 2018-06-30 | $74.54M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |